Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JAB-3068 |
| Synonyms | |
| Therapy Description |
JAB-3068 targets SHP2 (PTPN11) to inhibit MAPK signaling, which may decrease tumor cell proliferation (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JAB-3068 | JAB3068|JAB 3068 | SHP2 Inhibitor 20 | JAB-3068 targets SHP2 (PTPN11) to inhibit MAPK signaling, which may decrease tumor cell proliferation (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03518554 | Phase I | JAB-3068 | A First in Human, Dose Escalation Study of JAB-3068 in Adult Patients With Advanced Solid Tumors | Completed | USA | 0 |